Transcatheter aortic valve replacement (TAVR) appears to be safe in patients at low risk for surgical mortality who have bicuspid aortic stenosis, according to late-breaking trial results presented Monday at Cardiovascular Research Technologies (CRT) 2020 in National Harbor, Maryland.